Abstract:Background Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy have a worse prognosis than those who have no residual cancer. Trastuzumab emtansine (T‐DM1), an antibody–drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1), a maytansine derivative and microtubule inhibitor, provides benefit in patients with metastatic breast cancer that was previously treated with chemotherapy plus HER2‐targeted therapy. Methods We conducted a phase 3, open‐label trial involving patients with HER2‐positive early breast cancer who were found to have residual invasive disease in the breast or axilla at surgery after receiving neoadjuvant therapy containing a taxane (with or without anthracycline) and trastuzumab. Patients were randomly assigned to receive adjuvant T‐DM1 or trastuzumab for 14 cycles. The primary end point was invasive disease–free survival (defined as freedom from ipsilateral invasive breast tumor recurrence, ipsilateral locoregional invasive breast cancer recurrence, contralateral invasive breast cancer, distant recurrence, or death from any cause). Results At the interim analysis, among 1486 randomly assigned patients (743 in the T‐DM1 group and 743 in the trastuzumab group), invasive disease or death had occurred in 91 patients in the T‐DM1 group (12.2%) and 165 patients in the trastuzumab group (22.2%). The estimated percentage of patients who were free of invasive disease at 3 years was 88.3% in the T‐DM1 group and 77.0% in the trastuzumab group. Invasive disease–free survival was significantly higher in the T‐DM1 group than in the trastuzumab group (hazard ratio for invasive disease or death, 0.50; 95% confidence interval, 0.39 to 0.64; P<0.001). Distant recurrence as the first invasive‐disease event occurred in 10.5% of patients in the T‐DM1 group and 15.9% of those in the trastuzumab group. The safety data were consistent with the known safety profile of T‐DM1, with more adverse events associated with T‐DM1 than with trastuzumab alone. Conclusions Among patients with HER2‐positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant T‐DM1 than with trastuzumab alone. (Funded by F. Hoffmann–La Roche/Genentech; KATHERINE ClinicalTrials.gov number, NCT01772472.)

Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer

Pharmacology and clinical evaluation of ado-trastuzumab emtansine for the treatment of breast cancer

A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels

Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers

Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody-drug conjugate

Breast Cancer Treatment and Antibody Drug Conjugates: Beyond T-DM1

Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)

Trastuzumab Deruxtecan (T-Dxd) Vs Trastuzumab Emtansine (T-DM1) in Patients (pts) with HER2+ Metastatic Breast Cancer (mbc): Updated Survival Results of DESTINY-Breast03.

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

The role of ado-trastuzumab emtansine in current clinical practice

Preparation of trastuzumab-DM1 conjugate with a high drug-to-antibody ratio for breast cancer therapy

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance

Enhancing the Safety and Efficacy of Trastuzumab Emtansine (T‐DM1) Through Nano‐Delivery System in Breast Cancer Therapy

A DXd/TLR7-agonist dual-conjugate anti-HER2 ADC exerts robust anti-tumor activity through tumor cell killing and immune activation

Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy

The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer

T-DM1-induced thrombocytopenia in breast cancer patients: New perspectives

Ado-Trastuzumab Emtansine – The Monoclonal Drug Conjugate in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer